![Medtronic PROTECTA XT DR D314DRG Скачать руководство пользователя страница 198](http://html.mh-extra.com/html/medtronic/protecta-xt-dr-d314drg/protecta-xt-dr-d314drg_clinician-manual_1763148198.webp)
device to set the pacing amplitude just high enough to maintain capture while preserving
battery energy. For more information about Capture Management, see Section 7.5,
“Managing pacing output energies with Capture Management”, page 238.
Manually optimizing amplitude and pulse width – If you choose to program Capture
Management off, you can optimize the patient’s pacing output parameters manually.
Perform a pacing threshold test to determine the patient’s pacing thresholds. Select
amplitude and pulse width settings that provide an adequate safety margin above the
patient’s pacing threshold. This decreases the pacing outputs and preserves battery
energy. For more information about pacing thresholds, see Section 10.2, “Measuring pacing
thresholds”, page 425.
Pacing rate – The more paced events that are delivered, the more battery longevity is
reduced. Make sure that you have not programmed an unnecessarily high pacing rate for
the patient. Carefully consider using features that increase bradycardia pacing rate. Use
features such as Atrial Preference Pacing, Conducted AF Response, and Rate Response
only for patients who can receive therapeutic benefit from the feature.
6.15.3 Optimizing tachyarrhythmia therapy settings
Defibrillation – To treat ventricular fibrillation episodes, the device may deliver defibrillation
therapy to terminate the episode and restore the patient’s normal sinus rhythm. The device
may be programmed to deliver a sequence of up to 6 defibrillation therapies. Defibrillation
therapy expends a high level of energy. VF therapies should be programmed to the
maximum energy level. For more information about defibrillation therapy, see Section 9.1,
“Treating episodes detected as VF”, page 356.
Atrial cardioversion – You may choose to program the device to deliver automatic atrial
cardioversion (CV) therapies to treat atrial tachyarrhythmia episodes. If you choose to treat
the patient with atrial CV therapies, you may extend device longevity by carefully
considering how you program the following parameters: the number of shocks delivered
during a 24-hour cycle and the Episode Duration before CV. It is recommended that CV
therapy be set to full energy to terminate the arrhythmia. For more information about atrial
cardioversion, see Section 9.6, “Treating AT/AF with atrial cardioversion”, page 407.
Patient-activated cardioversion is another way to provide atrial cardioversion therapy. The
patient may use the Patient Assistant to signal the device to deliver atrial cardioversion
therapy as needed. Counsel the patient on the potential inappropriate overuse of
patient-activated cardioversion that may result in decreased device longevity. For more
information about patient-activated cardioversion, see Section 9.7, “Providing
patient-activated atrial cardioversion”, page 414.
Ventricular cardioversion – If you are providing ventricular cardioversion therapies for the
patient, consider programming the therapy energy to a value lower than the maximum
energy but high enough to terminate the VT. However, at least one VT therapy and one FVT
Medtronic
PROTECTA™ XT DR D314DRG
198
Clinician Manual
Содержание PROTECTA XT DR D314DRG
Страница 2: ......
Страница 9: ...Index 488 Medtronic PROTECTA XT DR D314DRG Clinician Manual 9 ...
Страница 506: ......
Страница 507: ......